Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular drug aficamten. Reports that ...
About Ho Chi Minh City Securities Corp. Ho Chi Minh City Securities Corp. engages in the provision of securities brokerage services for individual and institutional clients. It operates through the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback